论文部分内容阅读
加拿大卫生部(Health Canada)宣布已更新了七氟烷(Sevorane AF)的处方信息,以强调唐氏综合征儿童患者中可能发生心动过缓的情况。该药物的不同仿制药厂商目前正在着手更新其药品说明书。临床上七氟烷用于手术过程中的全身性麻醉剂,以使患者失去意识并无法感受到疼痛。加拿大卫生部发起了一项安全性评估,以评价唐氏综合征儿童中重度心率降低与使用全身麻醉剂七氟烷之间的潜在关联性。该问题是加拿大卫生部在对药品厂商提供的安全性信息定期评审时发现的。在评审时,加拿大卫生部未收到唐氏综合症
Health Canada announced that it has updated prescription information for Sevorane AF to emphasize possible bradycardia in children with Down Syndrome. Different generic manufacturers of the drug are currently working to update their drug specification. Sevoflurane is clinically used as a general anesthetic in surgery to make patients unconscious and unable to feel pain. Health Canada has launched a safety assessment to assess the potential association between the reduction of severe heart rates in children with Down Syndrome and the use of the general anesthetic sevoflurane. The problem was discovered by Health Canada during regular reviews of safety information provided by drug manufacturers. At the time of review, Health Canada did not receive Down’s syndrome